Medical Press Release - Page 10 of 12 - Medika Life : Keeping you informed

The Alkermes ALKS 3831 development program is part of our ongoing commitment to develop new therapeutic options for adults living with serious mental illness.

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

CATEGORIES

AI-Driven Model Supports Safer and More Precise Blood Sugar Management After Heart Surgery

Corundum Convergence Institute Launches to Catalyze Funding for Research and Innovation in Neuroscience and Systems Biology

StuffThatWorks and The Marfan Foundation to Engage in Pilot Program

Intellihealth Chief Medical Officer, Dr. Leon Igel, Honored as American Diabetes Association Greater New York Research Dinner Medical Honoree of the Year

LATEST

TRENDING

Medika’s Call for Food Aid for Starving Filipino Children

Lover, the App That Helps Women Reach Orgasm

ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis

The Nation’s Only Virtual At-Home Detox Programs from Workit Health Expands

The 50 Most Influential Leaders in Pharmacy 2022 Awards

SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults Approved

Reblozyl (luspatercept) Approved for Treatment of Transfusion-Dependent Anemia

Parnell Pharmaceuticals Announces Nomovid™ Antiviral Nasal Spray

Children with no COVID-19 symptoms may shed virus for weeks

South University Announces New MSPA Program at West Palm Beach Campus

EDITORS CHOICE

INOVIO’s COVID-19 Vaccine Shows Durable Antibody and T Cell Responses

Hepion Pharmaceuticals’ CRV431 Demonstrates Efficacy in Kidney Fibrosis

A New A.I. Based Solution to Nurse Burn-out and Turnover

Treatment for Schizophrenia and Bipolar I Disorder Gets Vote of Support

CONNECT WITH US ON SOCIAL MEDIA

Compliance

CORPORATE & MEDIA

Popular categories